These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 31258356)

  • 1. Relationship between 18-FDG-PET/CT and Clinicopathological Features and Pathological Responses in Patients with Locally Advanced Breast Cancers.
    Yildirim N; Simsek M; Aldemir MN; Bilici M; Tekin SB
    Eurasian J Med; 2019 Jun; 51(2):154-159. PubMed ID: 31258356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Value of
    Tatar G; Özkul Ö; Alçin G
    Mol Imaging Radionucl Ther; 2022 Jun; 31(2):123-129. PubMed ID: 35770978
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Role of 18F-FDG PET/CT in Predicting the Neoadjuvant Treatment Response in Patients with Locally Advanced Breast Cancer.
    Goktas Aydin S; Bilici A; Olmez OF; Oven BB; Acikgoz O; Cakir T; Basim P; Cakir A; Kutlu Y; Hamdard J
    Breast Care (Basel); 2022 Oct; 17(5):470-479. PubMed ID: 36684400
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Changes in 18F-FDG-PET/CT tumor metabolism are not consistent with pathologic complete response in hormone-positive breast cancer.
    Kaya S; Aktas B; Tanrikulu Sismek E; Akif Ozturk M; Dede F; Kaya H; Ugurlu U; Ozgen Z; Koca S; Halil S; Hasanov R; Alan O; Akgul Babacan N; Ercelep O; Dane F; Gumus M; Yumuk F
    J BUON; 2017; 22(5):1191-1198. PubMed ID: 29135102
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Value of 18F-FDG PET/CT Imaging Combined With Pretherapeutic Ki67 for Early Prediction of Pathologic Response After Neoadjuvant Chemotherapy in Locally Advanced Breast Cancer.
    Luo J; Zhou Z; Yang Z; Chen X; Cheng J; Shao Z; Guo X; Tuan J; Fu X; Yu X
    Medicine (Baltimore); 2016 Feb; 95(8):e2914. PubMed ID: 26937935
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of
    Akimoto E; Kadoya T; Kajitani K; Emi A; Shigematsu H; Ohara M; Masumoto N; Okada M
    Clin Breast Cancer; 2018 Feb; 18(1):45-52. PubMed ID: 28993056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Textural features of
    Cheng L; Zhang J; Wang Y; Xu X; Zhang Y; Zhang Y; Liu G; Cheng J
    Ann Nucl Med; 2017 Aug; 31(7):544-552. PubMed ID: 28646331
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficiency of fluorodeoxyglucose positron emission tomography/computed tomography to predict prognosis in breast cancer patients received neoadjuvant chemotherapy.
    Ishiba T; Nakagawa T; Sato T; Nagahara M; Oda G; Sugimoto H; Kasahara M; Hosoya T; Kubota K; Fujioka T; Danenberg P; Danenberg K; Uetake H
    Springerplus; 2015; 4():817. PubMed ID: 26722637
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Predictive Ability of
    Kiyoto S; Sugawara Y; Hosokawa K; Nishimura R; Yamashita N; Ohsumi S; Mochizuki T
    Asia Ocean J Nucl Med Biol; 2016; 4(1):3-11. PubMed ID: 27904868
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D; Sanna A; Majdoub M; de Cremoux P; Giacchetti S; Teixeira L; Espié M; Merlet P; de Roquancourt A; Visvikis D; Hatt M; Resche-Rigon M; Hindié E
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB; Pengel KE; Wesseling J; Vogel WV; Vrancken Peeters MJ; Vincent AD; Gilhuijs KG; Rodenhuis S; Rutgers EJ; Valdés Olmos RA
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancer.
    Groheux D; Biard L; Lehmann-Che J; Teixeira L; Bouhidel FA; Poirot B; Bertheau P; Merlet P; Espié M; Resche-Rigon M; Sotiriou C; de Cremoux P
    Eur J Nucl Med Mol Imaging; 2018 Jul; 45(8):1279-1288. PubMed ID: 29616304
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Subtype-Guided
    Wu S; Wang Y; Li J; Zhang N; Mo M; Klimberg S; Kaklamani V; Cochet A; Shao Z; Cheng J; Liu G
    Oncologist; 2020 Apr; 25(4):e626-e633. PubMed ID: 32297448
    [TBL] [Abstract][Full Text] [Related]  

  • 14.
    Groheux D; Martineau A; Teixeira L; Espié M; de Cremoux P; Bertheau P; Merlet P; Lemarignier C
    Breast Cancer Res; 2017 Jan; 19(1):3. PubMed ID: 28057031
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Complete Metabolic Response on Interim
    Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
    Oncologist; 2017 May; 22(5):526-534. PubMed ID: 28377466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. 18F-fluorodeoxyglucose (FDG) PET/CT after two cycles of neoadjuvant therapy may predict response in HER2-negative, but not in HER2-positive breast cancer.
    Cheng J; Wang Y; Mo M; Bao X; Zhang Y; Liu G; Zhang J; Geng D
    Oncotarget; 2015 Oct; 6(30):29388-95. PubMed ID: 26336821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. More advantages in detecting bone and soft tissue metastases from prostate cancer using
    Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
    Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of F-18 FDG PET/CT in Predicting Response to Neoadjuvant Chemotherapy in Invasive Ductal Breast Cancer.
    Sengoz T; Arman Karakaya Y; Gültekin A; Yilmaz S; Erdem E; Yapar Taskoylu B; Kesen Z; Yaylali O; Yuksel D
    Eur J Breast Health; 2023 Apr; 19(2):159-165. PubMed ID: 37025574
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
    Humbert O; Cochet A; Riedinger JM; Berriolo-Riedinger A; Arnould L; Coudert B; Desmoulins I; Toubeau M; Dygai-Cochet I; Guiu S; Coutant C; Fumoleau P; Brunotte F
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Initial Fludeoxyglucose (18F) Positron Emission Tomography-Computed Tomography (FDG-PET/CT) Imaging of Breast Cancer - Correlations with the Primary Tumour and Locoregional Metastases.
    Ayaz S; Gültekin SS; Ayaz ÜY; Dilli A
    Pol J Radiol; 2017; 82():9-16. PubMed ID: 28105247
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.